

## CLINICAL CANCER RESEARCH

## TABLE OF CONTENTS

## HIGHLIGHTS

- 903 Selected Articles from This Issue

## SPECIAL FEATURES

## CCR Translations

- 905 **Osimertinib plus Ramucirumab: The Best of Both Worlds?**  
Edward B. Garon  
See related article, p. 992
- 908 **Combined PD-1/VEGFR Blockade: A New Era of Treatment for Hepatocellular Cancer**  
David J. Pinato, Petros Fessas, Alessio Cortellini, and Lorenza Rimassa  
See related article, p. 1003
- 911 **Predicting CAR-T cell Immunotherapy Success through ImmunPET**  
Alessia Volpe, Veronica L. Nagle, Jason S. Lewis, and Vladimir Ponomarev  
See related article, p. 1058
- 913 **Transcription Strikes Back: Clinical Utility of Lung Adenocarcinoma Subtypes**  
Ferdinandos Skoulidis  
See related article, p. 1162

## CCR Perspectives in Regulatory Science and Policy

- 916 **FDA Oncology Center of Excellence Project Renewal: Engaging the Oncology Community to Update Product Labeling for Older Oncology Drugs**  
Paul G. Kluetz, Patricia Keegan, George D. Demetri, Katherine Thornton, Joohee Sul, Janice Kim, Harvey Katzen, Laurie Beth Burke, R. Donald Harvey, Eleni Alebachew, Sundeep Agrawal, Abhilasha Nair, Martha Donoghue, William F. Pierce, Stacy S. Shord, Jennifer J. Gao, and Richard Pazdur

## CCR Drug Updates

- 922 **FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma**  
Elaine Chang, Chana Weinstock, Lijun Zhang, Rosane Charlab, Sarah E. Dorff, Yutao Gong, Vicky Hsu, Fang Li, Tiffany K. Ricks, Pengfei Song, Shenghui Tang, Peter E. Waldron, Jingyu Yu, Eias Zahalka, Kirsten B. Goldberg, Richard Pazdur, Marc R. Theoret, Amna Ibrahim, and Julia A. Beaver
- 928 **FDA Approval Summary: Entrectinib for the Treatment of *NTRK* gene Fusion Solid Tumors**  
Leigh Marcus, Martha Donoghue, Stephanie Aungst, Claire E. Myers, Whitney S. Helms, Guoxiang Shen, Hong Zhao, Olen Stephens, Patricia Keegan, and Richard Pazdur

## Perspectives

- 933 **Optimizing the Use of Telemedicine in Oncology Care: Postpandemic Opportunities**  
Karen E. Knudsen, Cheryl Willman, and Robert Winn
- 937 **The Challenge of Combining Chemo- and Radiotherapy with Checkpoint Kinase Inhibitors**  
Linda van Bijsterveldt, Samuel C. Durley, Tim S. Maughan, and Timothy C. Humphrey
- 963 **WORLD CANCER RESEARCH DAY: A Call to Action for a Coordinated International Research Effort to Prevent, Diagnose, and Treat Cancer**  
Marta Puyol, Joan Seoane, Esther Aguilar, Lisa B. Vozza, Isabel Orbe, Katherine H. Crawford, Ana Fernández, Freddie Bray, Sonali E. Johnson, and Satish Gopal



# TABLE OF CONTENTS

## RESEARCH BRIEFS: CLINICAL TRIAL BRIEF REPORT

- 967** **A Randomized Phase IIb Study of Low-dose Tamoxifen in Chest-irradiated Cancer Survivors at Risk for Breast Cancer**  
Smita Bhatia, Melanie R. Palomares, Lindsey Hageman, Yanjun Chen, Wendy Landier, Kandice Smith, Heidi Umphrey, Caroline A. Reich, Kathryn W. Zamora, Saro H. Armenian, Therese B. Bevers, Anne Blaes, Tara Henderson, David Hodgson, Melissa M. Hudson, Larissa A. Korde, Susan A. Melin, Sofia D. Merajver, Linda Overholser, Sandhya Pruthi, F. Lennie Wong, and Judy E. Garber

## CLINICAL TRIALS: TARGETED THERAPY

- 975** **Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP)**  
Priyanka Sharma, Bruce F. Kimler, Anne O’Dea, Lauren Nye, Yen Y. Wang, Rachel Yoder, Joshua M. Staley, Lindsey Prochaska, Jamie Wagner, Amanda L. Amin, Kelsey Larson, Christa Balanoff, Manana Elia, Gregory Crane, Sheshadri Madhusudhana, Marc Hoffmann, Maureen Sheehan, Roberto Rodriguez, Karissa Finke, Rajvi Shah, Deepti Satelli, Anuj Shrestha, Larry Beck, Richard McKittrick, Robert Pluenneke, Vinay Raja, Venkatadri Beeki, Larry Corum, Jaimie Heldstab, Stephanie LaFaver, Micki Prager, Milind Phadnis, Dinesh Pal Mudarantakam, Roy A. Jensen, Andrew K. Godwin, Roberto Salgado, Kathan Mehta, and Qamar Khan
- 983** **Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer**  
Tanya E. Keenan, Tianyu Li, Tuulia Vallius, Jennifer L. Guerriero, Nabihah Tayob, Bose Kochupurakkal, Janae Davis, Ricardo Pastorello, Rie K. Tahara, Leilani Anderson, Jake Conway, Meng X. He, Erin Shannon, Robert E. Godin, Peter K. Sorger, Alan D’Andrea, Beth Overmoyer, Eric P. Winer, Elizabeth A. Mittendorf, Eliezer M. Van Allen, Geoffrey I. Shapiro, and Sara M. Tolane
- 992** **Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non-small Cell Lung Cancer**  
Helena A. Yu, Luis G. Paz-Ares, James Chih-Hsin Yang, Ki Hyeon Lee, Pilar Garrido, Keunchil Park, Joo-Hang Kim, Dae Ho Lee, Huzhang Mao, Sameera R. Wijayawardana, Ling Gao, Rebecca R. Hozak, Bo H. Chao, and David Planchard  
See related commentary, p. 905

## CLINICAL TRIALS: IMMUNOTHERAPY

- 1003** **Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial**  
Jianming Xu, Jie Shen, Shanzhi Gu, Yun Zhang, Lihua Wu, Jian Wu, Guoliang Shao, Yanqiao Zhang, Li Xu, Tao Yin, Jingfeng Liu, Zhenggang Ren, Jianping Xiong, Xianhai Mao, Ling Zhang, Jiayin Yang, Lequn Li, Xiaoming Chen, Zhiming Wang, Kangsheng Gu, Xi Chen, Zhanyu Pan, Kuansheng Ma, Xinmin Zhou, Zujiang Yu, Enxiao Li, Guowen Yin, Xiao Zhang, Shuni Wang, and Quanren Wang  
See related commentary, p. 908
- 1012** **A Phase I Trial of Talimogene Laherparepvec in Combination with Neoadjuvant Chemotherapy for the Treatment of Nonmetastatic Triple-Negative Breast Cancer**  
Hatem Soliman, Deanna Hogue, Hyo Han, Blaise Mooney, Ricardo Costa, Marie C. Lee, Bethany Niell, Angela Williams, Alec Chau, Shannon Falcon, Nazanin Khakpour, Robert J. Weinfurter, Susan Hoover, John Kiluk, Marilyn Rosa, Hung Khong, and Brian Czerniecki
- 1019** **Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy**  
Matthew D. Hellmann, Pasi A. Jänne, Mateusz Opyrchal, Navid Hafez, Luis E. Raez, Dmitry I. Gabrilovich, Fang Wang, Jane B. Trepel, Min-Jung Lee, Akira Yuno, Sunmin Lee, Susan Brouwer, Serap Sankoh, Lei Wang, David Tamang, Emmett V. Schmidt, Michael L. Meyers, Suresh S. Ramalingam, Elaine Shum, and Peter Ordentlich
- 1029** **Multicenter Phase I/II Study of Nivolumab Combined with Paclitaxel Plus Ramucirumab as Second-line Treatment in Patients with Advanced Gastric Cancer**  
 Takako Eguchi Nakajima, Shigenori Kadowaki, Keiko Minashi, Tomohiro Nishina, Takeharu Yamanaka, Yuichiro Hayashi, Naoki Izawa, Kei Muro, Shuichi Hironaka, Takeshi Kajiwara, and Yutaka Kawakami
- 1037** **Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial**  
Anne Montfort, Thomas Filleron, Mathieu Virazels, Carine Dufau, Jean Milhès, Cécile Pagès, Pascale Olivier, Maha Ayyoub, Muriel Mounier, Amélie Lusque, Stéphanie Brayer, Jean-Pierre Delord, Nathalie Andrieu-Abadie, Thierry Levade, Céline Colacios, Bruno Ségui, and Nicolas Meyer

# TABLE OF CONTENTS

- 1048**     **Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma**  
Lakshmi Nayak, Annette M. Molinaro, Katherine Peters, Jennifer L. Clarke, Justin T. Jordan, John de Groot, Leia Nghiemphu, Thomas Kaley, Howard Colman, Christine McCluskey, Sarah Gaffey, Timothy R. Smith, David J. Cote, Mariano Severgnini, Jennifer H. Yearley, Qing Zhao, Wendy M. Blumenschein, Dan G. Duda, Alona Muzikansky, Rakesh K. Jain, Patrick Y. Wen, and David A. Reardon

## PRECISION MEDICINE AND IMAGING

- 1058**     **Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET**  
**A C** Federico Simonetta, Israt S. Alam, Juliane K. Lohmeyer, Bitu Sahaf, Zinaida Good, Weiyu Chen, Zunyu Xiao, Toshihito Hirai, Lukas Scheller, Pujan Engels, Ophir Vermesh, Elise Robinson, Tom Haywood, Ataya Sathirachinda, Jeanette Baker, Meena B. Malipatlolla, Liora M. Schultz, Jay Y. Spiegel, Jason T. Lee, David B. Miklos, Crystal L. Mackall, Sanjiv S. Gambhir, and Robert S. Negrin  
See related commentary, p. 911
- 1069**     **Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer**  
Sara A. Väyrynen, Jinming Zhang, Chen Yuan, Juha P. Väyrynen, Andressa Dias Costa, Hannah Williams, Vicente Morales-Oyarvide, Mai Chan Lau, Douglas A. Rubinson, Richard F. Dunne, Margaret M. Kozak, Wenjia Wang, Diana Agostini-Vulaj, Michael G. Drage, Lauren Brais, Emma Reilly, Osama Rahma, Thomas Clancy, Jiping Wang, David C. Linehan, Andrew J. Aguirre, Charles S. Fuchs, Lisa M. Coussens, Daniel T. Chang, Albert C. Koong, Aram F. Hezel, Shuji Ogino, Jonathan A. Nowak, and Brian M. Wolpin
- 1082**     **Defining the Comprehensive Genomic Landscapes of Pancreatic Ductal Adenocarcinoma Using Real-World Endoscopic Aspiration Samples**  
Alexander Semaan, Vincent Bernard, Jaewon J. Lee, Justin W. Wong, Jonathan Huang, Daniel B. Swartzlander, Bret M. Stephens, Maria E. Monberg, Brian R. Weston, Manoop S. Bhutani, Kyle Chang, Paul A. Scheet, Anirban Maitra, Yasminka A. Jakubek, and Paola A. Guerrero

- 1094**     **Discrimination of Breast Cancer from Healthy Breast Tissue Using a Three-component Diffusion-weighted MRI Model**  
Maren M. Sjaastad Andreassen, Ana E. Rodríguez-Soto, Christopher C. Conlin, Igor Vidić, Tyler M. Seibert, Anne M. Wallace, Somaye Zare, Joshua Kuperman, Boya Abudu, Grace S. Ahn, Michael Hahn, Neil P. Jerome, Agnes Østlie, Tone F. Bathen, Haydee Ojeda-Fournier, Pål Erik Goa, Rebecca Rakow-Penner, and Anders M. Dale

- 1105**     **Genomic Characterization of *de novo* Metastatic Breast Cancer**  
Ana C. Garrido-Castro, Liam F. Spurr, Melissa E. Hughes, Yvonne Y. Li, Andrew D. Cherniack, Priti Kumari, Maxwell R. Lloyd, Brittany Bychkovsky, Romualdo Barroso-Sousa, Simona Di Lascio, Esha Jain, Janet Files, Ayesha Mohammed-Abreu, Max Krevalin, Colin MacKichan, William T. Barry, Hao Guo, Daniel Xia, Ethan Cerami, Barrett J. Rollins, Laura E. MacConaill, Neal I. Lindeman, Ian E. Krop, Bruce E. Johnson, Nikhil Wagle, Eric P. Winer, Deborah A. Dillon, and Nancy U. Lin

- 1119**     **Early Adaptation of Colorectal Cancer Cells to the Peritoneal Cavity Is Associated with Activation of “Stemness” Programs and Local Inflammation**  
**A C** Jorge Barriuso, Raghavendar T. Nagaraju, Shreya Belgamwar, Bipasha Chakrabarty, George J. Burghel, Helene Schlecht, Lucy Foster, Elaine Kilgour, Andrew J. Wallace, Michael Braun, Caroline Dive, D. Gareth Evans, Robert G. Bristow, Mark P. Saunders, Sarah T. O’Dwyer, and Omer Aziz

- 1131**     **Deep Learning Predicts HPV Association in Oropharyngeal Squamous Cell Carcinomas and Identifies Patients with a Favorable Prognosis Using Regular H&E Stains**  
Sebastian Klein, Alexander Quaas, Jennifer Quantius, Heike Löser, Jörn Meinel, Martin Peifer, Steffen Wagner, Stefan Gattenlöhner, Claus Wittekindt, Magnus von Knebel Doeberitz, Elena-Sophie Prigge, Christine Langer, Ka-Won Noh, Margaret Maltseva, Hans Christian Reinhardt, Reinhard Büttner, Jens Peter Klussmann, and Nora Wuerdemann

## TRANSLATIONAL CANCER MECHANISMS AND THERAPY

- 1139**     **Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth *In Vitro* and *In Vivo***  
Eleni Anastasiadou, Anita G. Seto, Xuan Beatty, Melanie Hermreck, Maud-Emmanuelle Gilles, Dina Stroopinsky, Lauren C. Pinter-Brown, Linda Pestano, Cinzia Marchese, David Avigan, Pankaj Trivedi, Diana M. Escobar, Aimee L. Jackson, and Frank J. Slack


# TABLE OF CONTENTS

- 1150**     **ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma**  
Yuta Myojin, Takahiro Kodama, Kazuki Maesaka, Daisuke Motooka, Yu Sato, Satoshi Tanaka, Yuichi Abe, Kazuyoshi Ohkawa, Eiji Mita, Yoshito Hayashi, Hayato Hikita, Ryotaro Sakamori, Tomohide Tatsumi, Ayumu Taguchi, Hidetoshi Eguchi, and Tetsuo Takehara
- 1162**     **Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma**  
**A C**     Anneleen Daemen, Jonathan E. Cooper, Szymon Myrta, Matthew J. Wongchenko, Eva Lin, Jason E. Long, Oded Foreman, Zora Modrusan, Jarrod R. Tremayne, Cecile C. de la Cruz, Mark Merchant, Scott E. Martin, Yibing Yan, and Melissa R. Junttila  
See related commentary, p. 913
- 1174**     **Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer**  
**A C**     Jim P. Abraham, Daniel Magee, Chiara Cremolini, Carlotta Antoniotti, David D. Halbert, Joanne Xiu, Phillip Stafford, Donald A. Berry, Matthew J. Oberley, Anthony F. Shields, John L. Marshall, Mohamed E. Salem, Alfredo Falcone, Axel Grothey, Michael J. Hall, Alan P. Venook, Heinz-Josef Lenz, Anthony Helmstetter, W. Michael Korn, and David B. Spetzler
- 1184**     **Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor**  
Koichi Ogura, Romel Somwar, Julija Hmeljak, Heather Magnan, Ryma Benayed, Amir Momeni Boroujeni, Anita S. Bowman, Marissa S. Mattar, Inna Khodos, Elisa de Stanchina, Achim Jungbluth, Marina Asher, Igor Odintsov, Alifiani B. Hartono, Michael P. LaQuaglia, Emily Slotkin, Christine A. Pratilas, Sean Bong Lee, Lee Spraggon, and Marc Ladanyi
- 1195**     **Impact of Body Mass Index on Presence of ctDNA and Disease Recurrence after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Analysis from BRE12-158**  
Tarah J. Ballinger, Guanglong Jiang, Nawal Kassem, Milan Radovich, and Bryan P. Schneider
- 1200**     **Somatic Epigenetic Silencing of *RIPK3* Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma**  
Yinfei Tan, Eleonora Sementino, Mitchell Cheung, Suraj Peri, Craig W. Menges, Anna-Mariya Kukuyan, Ting Zhang, Vladimir Khazak, Lauren A. Fox, Eric A. Ross, Suresh Ramanathan, Suresh C. Jhanwar, Raja M. Flores, Siddharth Balachandran, and Joseph R. Testa

**A C** AC icon indicates AuthorChoice  
For more information please visit [www.aacrjournals.org](http://www.aacrjournals.org)

## ABOUT THE COVER

The cover shows a section of a liver metastasis biopsy from a patient with triple-negative breast cancer. Cyclic immunofluorescence shows high phosphorylated CDK1/2/3/5 (*red*) and low phospho-histone H3 (*green*) in pan-cytokeratin (*white*)-positive tumor cells after treatment with cisplatin. These markers switched in a site-matched biopsy at a later timepoint after the addition of the WEE1 inhibitor adavosertib, which is further described. For details, see the article by Keenan and colleagues on page 983 of this issue.



# Clinical Cancer Research

**27 (4)**

*Clin Cancer Res* 2021;27:903-1213.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/27/4>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/27/4>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.